@stockrock
"So it won't be just the futility outcome, it will be everything they have on the CHF program to date, of which the futility test forms part of."
Yes I take your point, so their main selling point to the FDA will be the phase 2 findings for MACE for the 150m group over 36 months, plus the follow-up that they will finish the phase 3 trial(s) with good results.
They hope these 2 points, plus the safety of the treatment, will convince the FDA to allow an early market entry.
Call with Mesoblast re CHF interim, page-7
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |